SCHEMBL2965348

SCHEMBL2965348

CC(O)c1cccc(Oc2ccc(Cl)cc2N)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.63
CYP1A2 P05177 2/20 0.59
CYP2C9 P11712 2/20 0.59
CYP2C19 P33261 2/20 0.59
CYP3A4 P08684 1/20 0.59
MAPT P10636 4/20 0.54
LMNA P02545 1/20 0.54
HTT P42858 1/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ALDH1A1 P00352 2/20 0.53
KDM4E B2RXH2 1/20 0.53
CYP2D6 P10635 1/20 0.53
HPGD P15428 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
P2RX4 Q99571 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
PTGER4 P35408 2/20 0.41
GAA P10253 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13190827 0.87 L3MBTL1 (0.65) L3MBTL1CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL811122 0.84 MAPT (0.66) L3MBTL1CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL5315212 0.79 PTGS1 (0.51) LMNAHTTMEN1KMT2AALDH1A1
SCHEMBL2962809 0.78 PDE7A (0.54) MAPTLMNAHTTMEN1KMT2A
SCHEMBL359171 0.78 CYP1A2 (0.68) L3MBTL1CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL13190865 0.77 L3MBTL1 (0.49) L3MBTL1CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL6912472 0.77 PTGS1 (0.58) L3MBTL1MEN1KMT2ACYP2D6PTGS1
SCHEMBL6912468 0.77 PTGS1 (0.58) L3MBTL1MEN1KMT2ACYP2D6PTGS1
SCHEMBL1049056 0.76 PTGS1 (0.47) MEN1KMT2ACYP2D6PTGS1RHEB
SCHEMBL2967362 0.76 MAPT (0.72) L3MBTL1CYP1A2CYP2C9CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 L3MBTL1 2884/4885CYP1A2 877/4885CYP2C9 738/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 L3MBTL1 2884/4885CYP1A2 877/4885CYP2C9 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.